Your browser doesn't support javascript.
loading
A Protocol for the Inclusion of Minoritized Persons in Alzheimer Disease Research From the ADNI3 Diversity Taskforce.
Okonkwo, Ozioma C; Rivera Mindt, Monica; Ashford, Miriam T; Conti, Catherine; Strong, Joe; Raman, Rema; Donohue, Michael C; Nosheny, Rachel L; Flenniken, Derek; Miller, Melanie J; Diaz, Adam; Soto, Annabelle M; Ances, Beau M; Beigi, Maryam R; Doraiswamy, P Murali; Duara, Ranjan; Farlow, Martin R; Grossman, Hillel T; Mintzer, Jacobo E; Reist, Christopher; Rogalski, Emily J; Sabbagh, Marwan N; Salloway, Stephen; Schneider, Lon S; Shah, Raj C; Petersen, Ronald C; Aisen, Paul S; Weiner, Michael W.
Afiliação
  • Okonkwo OC; Department of Medicine and Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison.
  • Rivera Mindt M; Department of Psychology, Latin American Latinx Studies Institute, and African and African American Studies, Fordham University, Bronx, New York.
  • Ashford MT; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Conti C; Northern California Institute for Research and Education, Department of Veterans Affairs Medical Center, San Francisco.
  • Strong J; VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, California.
  • Raman R; Northern California Institute for Research and Education, Department of Veterans Affairs Medical Center, San Francisco.
  • Donohue MC; VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, California.
  • Nosheny RL; Department of Medicine and Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison.
  • Flenniken D; Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego.
  • Miller MJ; Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego.
  • Diaz A; VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, California.
  • Soto AM; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco.
  • Ances BM; Northern California Institute for Research and Education, Department of Veterans Affairs Medical Center, San Francisco.
  • Beigi MR; VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, California.
  • Doraiswamy PM; Northern California Institute for Research and Education, Department of Veterans Affairs Medical Center, San Francisco.
  • Duara R; VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, California.
  • Farlow MR; Northern California Institute for Research and Education, Department of Veterans Affairs Medical Center, San Francisco.
  • Grossman HT; VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, California.
  • Mintzer JE; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Reist C; Department of Neurology, Washington University in Saint Louis, Saint Louis, Missouri.
  • Rogalski EJ; Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles.
  • Sabbagh MN; Departments of Psychiatry and Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Salloway S; Wein Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, Florida.
  • Schneider LS; Herbert Wertheim College of Medicine, Florida International University, Miami.
  • Shah RC; Alzheimer's Disease Research Center, University of Florida College of Medicine, Gainesville.
  • Petersen RC; Department of Neurology, Indiana University Health, Indianapolis.
  • Aisen PS; The Alzheimer Disease Research Center, Mount Sinai School of Medicine, New York, New York.
  • Weiner MW; Medical University of South Carolina, Ralph H. Johnson VA Healthcare Center, Charleston.
JAMA Netw Open ; 7(8): e2427073, 2024 Aug 01.
Article em En | MEDLINE | ID: mdl-39120898
ABSTRACT
Importance Black or African American (hereinafter, Black) and Hispanic or Latino/a/x (hereinafter, Latinx) adults are disproportionally affected by Alzheimer disease, but most research studies do not enroll adequate numbers of both of these populations. The Alzheimer's Disease Neuroimaging Initiative-3 (ADNI3) launched a diversity taskforce to pilot a multipronged effort to increase the study inclusion of Black and Latinx older adults.

Objective:

To describe and evaluate the culturally informed and community-engaged inclusion efforts to increase the screening and enrollment of Black and Latinx older adults in ADNI3. Design, Setting, and

Participants:

This cross-sectional study used baseline data from a longitudinal, multisite, observational study conducted from January 15, 2021, to July 12, 2022, with no follow-up. The study was conducted at 13 ADNI3 sites in the US. Participants included individuals aged 55 to 90 years without cognitive impairment and those with mild cognitive impairment or Alzheimer disease. Exposures Efforts included (1) launch of an external advisory board, (2) changes to the study protocol, (3) updates to the digital prescreener, (4) selection and deployment of 13 community-engaged research study sites, (5) development and deployment of local and centralized outreach efforts, and (6) development of a community-science partnership board. Main Outcomes and

Measures:

Screening and enrollment numbers from centralized and local outreach efforts, digital advertisement metrics, and digital prescreener completion.

Results:

A total of 91 participants enrolled in the trial via centralized and local outreach efforts, of which 22 (24.2%) identified as Latinx and 55 (60.4%) identified as Black (median [IQR] age, 65.6 [IQR, 61.5-72.5] years; 62 women [68.1%]). This represented a 267.6% increase in the monthly rate of enrollment (before 1.11 per month; during 4.08 per month) of underrepresented populations. For the centralized effort, social media advertisements were run between June 1, 2021, and July 31, 2022, which resulted in 2079 completed digital prescreeners, of which 1289 met criteria for subsequent site-level screening. Local efforts were run between June 1, 2021, to July 31, 2022. A total of 151 participants underwent site-level screening (100 from local efforts, 41 from centralized efforts, 10 from other sources). Conclusions and Relevance In this cross-sectional study of pilot inclusion efforts, a culturally informed, community-engaged approach increased the inclusion of Black and Latinx participants in an Alzheimer disease cohort study.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Negro ou Afro-Americano / Hispânico ou Latino / Doença de Alzheimer Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Negro ou Afro-Americano / Hispânico ou Latino / Doença de Alzheimer Idioma: En Ano de publicação: 2024 Tipo de documento: Article